A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61K 31/00 (2006.01) A61P 35/00 (2006.01) C07K 16/24 (2006.01) C07K 16/28 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2404365
The present invention discloses combined therapies for treating hematologic malignancies, including B cell lymphomas and leukemias or solid non- hematologic tumors, comprising administration of anti-cytokine antibodies or antagonists to inhibit the activity of cytokines which play a role in perpetuating the activation of B cells. The administration of such antibodies and antagonists, particularly anti-IL10 antibodies and antagonists, is particularly useful for avoiding or decreasing the resistance of hematologic malignant cells or solid tumor cells to chemotherapeutic agents and anti-CD20 or anti-CD22 antibodies. The invention also provides combination therapies for solid tumors having B cell involvement comprising the administration of an anti-cytokine antibody and a B cell depleting antibody such as RITUSAN®.
La présente invention concerne des thérapies combinées pour le traitement de malignités hématologiques, dont les lymphomes B les leucémies, ou de tumeurs non hématologiques solides. Ces thérapies qui consistent à administrer des anticorps et des antagonistes anti-cytokine pour inhiber l'activité de cytokines qui contribuent à perpétuer l'activation des cellules of B. L'administration de tels anticorps et antagonistes, en particulier d'anticorps et d'antagonistes anti-IL10, convient particulièrement bien pour inhiber ou affaiblir la résistance des cellules malignes hématologiques ou des cellules de tumeur solide à des agents chimiothérapeutiques et à des anticorps anti-CD20 ou anti-CD22. Cette invention concerne également des thérapies combinées dirigées contre des tumeurs solides dans lesquelles interviennent des cellules B et qui comprennent l'administration d'un anticorps à action déplétive sur les cellules B tel que RITUSAN®.
Biogen Idec Inc.
Gowling Lafleur Henderson Llp
Idec Pharmaceutical Corporation
LandOfFree
Combined use of anti-cytokine antibodies or antagonists and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combined use of anti-cytokine antibodies or antagonists and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined use of anti-cytokine antibodies or antagonists and... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1600910